文献速递乳腺乳腺X线

68-69岁末次阴性筛查钼靶后5年乳腺癌年发病率及临床分子特征

Five-year annual incidence and clinico-molecular features of breast cancer after the last negative screening mammography at age 68-69.
PubMed 文献 · Eur Radiol · 2021-08-06

该队列纳入118,370名意大利女性,末次双年筛查钼靶在68-69岁,随访5年。间隔癌比例发病在第1年0.09,第3年0.60,第5年0.81;第2至5年肿瘤分期和分子亚型无显著变化。

要点

  • 70-74岁女性三年度筛查的推荐证据非常弱,第3年间隔癌比例发病0.60(95%CI 0.49-0.73)。
  • 第2至第5年间隔癌的肿瘤分期和分子亚型无显著变化(p>0.10)。
  • 第3年比例发病95%CI上限0.73超过50-69岁可接受上限0.50,支持进一步研究。

诊断标准与关键数值

  • 间隔癌比例发病=观察到的间隔癌数/预期发病数;第1年0.09(95%CI 0.06-0.13),第2年0.32(0.25-0.39),第3年0.60(0.49-0.73),第4年0.75(0.60-0.92),第5年0.81(0.60-1.07)。
  • 50-69岁女性可接受的比例发病上限为0.50;第3年95%CI包含0.50。

临床应用与阅片要点

  • 对于70-74岁女性,若采用三年度筛查间隔,第3年间隔癌比例发病接近可接受上限,需关注筛查间期肿瘤风险。
  • 随访第2至5年肿瘤分期和分子亚型稳定,提示间隔癌的生物学特征未随时间显著恶化。

局限性

  • 三年度筛查推荐基于非常弱的证据;本研究为观察性队列,非随机对照试验。
  • 研究假设5年随访代表至另一次假设筛查的间隔,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The European Commission Initiative on Breast Cancer recommendation for triennial screening of women aged 70-74 is based on very weak evidence. A cohort of Italian women who had their last biennial screening mammography at age 68-69 was followed up for 5 years, assumed to represent the interval to another hypothetical screening mammography, in order to determine the annual proportional incidence of interval breast cancer.

METHODS: The cohort included 118,370 women. They had their last mammography between 1997 and 2008. Incident breast cancers were identified by record-linking the cohort with the regional breast cancer registry. The expected incidence in the age range 65-74 was estimated with an age-period-cohort model. The number of interval cancers was divided by the expected number to obtain their proportional incidence.

RESULTS: Overall, there were 298,658 woman-years at risk with 371 interval cancers versus 988.8 expected. In the first, second, third, fourth, and fifth interval year, the proportional incidence was 0.09 (95% confidence interval, 0.06-0.13), 0.32 (0.25-0.39), 0.60 (0.49-0.73), 0.75 (0.60-0.92), and 0.81 (0.60-1.07), respectively. Between the second and the fifth year, tumour stage and molecular subtype did not change significantly.

CONCLUSION: Though not supported by these findings, the proposal of triennial screening for women aged 70-74 merits further research, because the 95% confidence interval of the third-year proportional incidence of interval cancer included 0.50-the maximum limit considered acceptable for women aged 50-69.

KEY POINTS: • The third-year incidence of breast cancer relative to the expected one was 0.60 (95% confidence interval, 0.49-0.73). • Between the second and the fifth year, tumour stage and molecular subtype did not change significantly (p >0.10). • The proposal of a 3-year screening interval at age 70-74 merits further evaluation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bucchi L, Ravaioli A, Baldacchini F, et al. Five-year annual incidence and clinico-molecular features of breast cancer after the last negative screening mammography at age 68-69. Eur Radiol. 2021. PMID: 34363132. doi:10.1007/s00330-021-08129-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。